Photo from wikipedia
Natriuretic peptides (NPs) are now routinely incorporated as key inclusion criteria in clinical trials of heart failure with preserved ejection fraction (HFpEF) as objective measures of risk. An early amendment… Click to show full abstract
Natriuretic peptides (NPs) are now routinely incorporated as key inclusion criteria in clinical trials of heart failure with preserved ejection fraction (HFpEF) as objective measures of risk. An early amendment in PARAGON‐HF required all participants to have elevated NP concentrations, but some were enrolled pre‐amendment, providing a unique opportunity to understand the influence of enrolment pathway in HFpEF clinical trials.
Keywords:
failure preserved;
heart failure;
inclusion criteria;
clinical trials
Journal Title: European Journal of Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!